BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs

AstraZeneca lands a third consecutive Phase 3 win in bladder cancer — event-free survival and overall survival — putting Imfinzi on a direct collision course with Merck's Keytruda.

Meanwhile, gene therapy had a split-screen day. Breakthrough Duchenne data and seizure reduction in Dravet, right alongside scientists linking a brain tumor to a viral vector — and an FDA without a permanent commissioner to sort any of it out.

Welcome to The Pharma Closeout for Thursday, May 14, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it. ### [TOP STORY] — AstraZeneca VOLGA Phase 3 Results in Bladder Cancer

Start with AstraZeneca. The VOLGA Phase 3 trial read out this morning — perioperative Imfinzi combined with neoadjuvant Padcev hit both co-primary endpoints, event-free survival and overall survival, versus standard of care in cisplatin-ineligible muscle-invasive bladder cancer. No new safety signals. That's AZ's third consecutive Phase 3 win in this disease, a remarkable turnaround from pulling their original accelerated approval back in 2021.

The doublet arm is the clean story. The triplet — adding Imjudo, AZ's CTLA-4 inhibitor — showed significant event-free survival improvement, but overall survival did not reach statistical significance at the interim analysis. AZ called it a favorable trend, which in interim-analysis language means directionally right but statistically premature.

The competitive clock is ticking. Merck already holds a perioperative approval for Keytruda plus Padcev in the cisplatin-ineligible population established earlier this year. And the same Keytruda-Padcev combination is under FDA priority review for cisplatin-eligible patients, with an August 17th PDUFA.

The Imjudo question is where this gets clinically interesting. These are cisplatin-ineligible patients — often renally impaired, lower performance status, carrying a heavier comorbidity load. If the doublet already delivers OS in that population, layering CTLA-4 on top has to justify its incremental toxicity with a survival separation that simply isn't there yet.

AZ plans to present full data at an upcoming medical meeting and share results with regulators. But here's the commercial reality — every month AZ trails Merck's label expansion is a month of urologist prescribing habits forming around Keytruda. That gap matters more than the p-value.

And structurally, both regimens are built around Padcev. Pfizer and Astellas are positioned to capture ADC revenue regardless of which checkpoint inhibitor wins share. The quiet winners in this rivalry aren't even at the podium.

That Padcev point actually connects to the broader deal picture this week, because the flow has been relentless. Start with Bristol Myers and China's Hengrui — they formalized an alliance covering up to 13 assets with a headline value up to $15.2 billion. That makes it the second-largest China licensing deal on record, behind only AstraZeneca's $18.5 billion pact with CSPC in January. And this while pharma CEOs were notably absent from the President's China trip earlier this week.

Thirteen assets in a single pact is not a partnership — it's a pipeline acquisition structured as optionality. BMS gets shots on goal across multiple mechanisms while keeping the upfront exposure manageable relative to the total deal value.

On the approval side, BeOne's Beqalzi — the BCL-2 inhibitor sonrotoclax — cleared the FDA yesterday for relapsed or refractory mantle cell lymphoma after at least two prior lines including a BTK inhibitor. A novel drug expected in 2026 that positions itself as a direct challenger to AbbVie and Roche's Venclexta franchise.

Mantle cell is the entry point, not the destination. The real question is how fast BeOne moves into CLL and AML — the indications where Venclexta actually generates its revenue.

Quick hits — MacroGenics is selling its GMP manufacturing operations to Bora Pharmaceuticals for a substantial upfront payment. Takeda detailed an ambitious restructuring plan targeting substantial cost savings through 2028, with significant near-term reductions expected this year, meaningful workforce reductions coming in fiscal 2026, and a new CEO set to arrive imminently. BioAge, after axing its lead obesity program, pivoted entirely to inflammation and aging-related disease. And Alphabet's Isomorphic Labs, the DeepMind drug discovery spinout, raised north of $2 billion — AI-native drug discovery is now a capital formation category, not a thesis.

Run the numbers on the biotech capital markets, though, and the picture isn't all retrenchment. Nine of the eleven biotechs to IPO this year have raised at least $250 million — the strongest pace since 2021. Institutional appetite for clinical-stage biotech hasn't cooled, it's gotten far more selective about what clears the bar. That selectivity is what's sustaining the window.

Meanwhile, markets were muted today. Drug manufacturers down about a third of a percent, biotech off by a similar amount, both trailing the S&P. The hantavirus-driven biotech spike from earlier this week fully faded — Novavax and Emergent BioSolutions each gave back their gains, down five percent and one percent respectively after the initial surge.

On the regulatory side, a full plate. Taiho's Inqovi picked up a label expansion into AML, now approved in combination with venetoclax for newly diagnosed patients ineligible for intensive induction chemotherapy. Per the filing, that creates the first all-oral combination regimen for that population. For patients who struggle with the infusion burden of IV hypomethylating agents, this is an access expansion — it changes who actually gets treated, not just how. Separately, the FDA published a new framework for repurposing older approved drugs under new indications, leveraging existing safety databases to compress development timelines. Worth watching for specialty pharma and generics companies sitting on mature portfolios.

The bigger regulatory story today, though, is gene therapy — and it's layered. Regenxbio reported that RGX-202 met its primary endpoint in the pivotal Phase 3 Duchenne muscular dystrophy trial and plans to file for accelerated approval. But two serious adverse events clouded the readout.

CEO Curran Simpson claimed FDA leadership will carry a mandate on rare disease flexibility — and that framing deserves scrutiny. This is the same Regenxbio that received a complete response letter on RGX-121 for MPS II back in February, where the FDA cited concerns about eligibility criteria, the natural history control, and the validity of the surrogate endpoint. The agency's gene therapy bar hasn't softened.

And it may have just gotten higher. Scientists linked a boy's brain tumor to the viral delivery vector used in his gene therapy, per STAT News reporting. Insertional oncogenesis just moved from a theoretical risk model to a documented clinical event.

Contrast that with Encoded Therapeutics presenting ASGCT data on ETX101 for Dravet syndrome, showing seizure reduction. ETX101 targets SCN1A haploinsufficiency, upregulating expression in inhibitory interneurons. If that signal holds across dose escalation cohorts, it's a compelling proof of concept for monogenic epilepsy gene therapy. But the vector safety overhang now sits over every AAV program in development — not just these two.

And all of this lands at an agency without a permanent commissioner. Biopharma voices are rallying behind Richard Pazdur — the longtime oncology review chief, architect of much of the accelerated approval framework — but he left the agency during the Makary era after publicly warning that the firewall between political appointees and drug review had eroded.

Until that leadership question resolves, every gene therapy BLA carries a regulatory variable that has nothing to do with the underlying science. And for companies like Regenxbio trying to thread the accelerated approval needle in rare disease, that uncertainty compounds the clinical risk they're already managing. It's the definition of a bad time to have a leadership vacuum.

Looking ahead — August 17th, mark it. That's the PDUFA for Merck's Keytruda-Padcev combination in cisplatin-eligible muscle-invasive bladder cancer. If that clears before AZ can bring VOLGA data to regulators, Merck locks up both halves of the MIBC population first, and the Imfinzi commercial launch becomes an uphill share fight from day one. Separately, Kyverna Therapeutics is reportedly preparing what's described as a first-of-its-kind approval application for CAR-T in autoimmune disease — if the FDA accepts that filing, it opens a new regulatory pathway for engineered cell therapies beyond oncology.

Also on the radar — Biogen is pressing forward with diranersen, their anti-tau Alzheimer's therapy, despite the CELIA Phase 2 missing its primary endpoint. The company points to encouraging signals of slowed clinical decline and tau reduction, with comprehensive data readout anticipated at AAIC in July. And the gene therapy safety conversation unfolding at ASGCT this week could reshape how the FDA evaluates risk-benefit across the entire AAV platform for months to come.

That is your Pharma Closeout for Thursday. AstraZeneca rebuilding its bladder cancer franchise with VOLGA, BMS locking down a $15.2 billion China pipeline play, BeOne's Beqalzi taking aim at Venclexta, and gene therapy navigating its most complicated day of the year — breakthrough data and a documented safety signal in the same news cycle. If this briefing helps you stay across the space, follow us on Spotify and drop a rating — it's how others in pharma find us. We're back tomorrow.

Enjoy your Thursday evening. See you tomorrow. ### Episode Metadata **Title:** AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang; Pazdur for FDA Commissioner | May 14, 2026 **Description:** AstraZeneca's VOLGA trial hits EFS and OS in cisplatin-ineligible bladder cancer, putting Imfinzi squarely in Keytruda's lane. Plus: Regenxbio's Duchenne gene therapy heads for FDA filing amid safety signals, a brain tumor linked to a viral vector raises AAV concerns, and biopharma rallies behind Richard Pazdur for FDA commissioner. Also: BMS-Hengrui $15.2B alliance, BeOne's Beqalzi challenges Venclexta, and Taiho's Inqovi expands into AML. **Tags:** AstraZeneca, Imfinzi, durvalumab, bladder cancer, VOLGA, Merck, Keytruda, Padcev, Pfizer, Regenxbio, RGX-202, Duchenne muscular dystrophy, gene therapy, BeOne, Beqalzi, sonrotoclax, Venclexta, Taiho, Inqovi, AML, FDA commissioner, Richard Pazdur, Encoded Therapeutics, Dravet syndrome, ETX101, BMS, Hengrui, Takeda, MacroGenics, BioAge, Isomorphic Labs, Kyverna, Biogen, diranersen, Alzheimer's, ASGCT, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #